Day One Biopharmaceuticals Inc
DAWN6.780USD
+0.130+1.95%
交易中 （美东）报价延迟15分钟
687.18M总市值
亏损市盈率 TTM
关于 Day One Biopharmaceuticals Inc 公司
Day One Biopharmaceuticals, Inc. 是一家临床阶段的生物制药公司，专注于为患有危及生命的疾病的所有年龄段人群开发和商业化靶向疗法。该公司与临床肿瘤学家、家属和科学家合作，以确定、获取和开发癌症治疗方法。其候选产品包括托沃拉非尼、pimasertib 和 VRK1 项目。该公司的主要候选产品托沃拉非尼是一种口服、脑渗透性、高选择性 II 型 RAF 激酶抑制剂。该公司的产品线还包括 pimasertib，这是一种口服、高选择性的丝裂原活化蛋白激酶 1 和 2 (MEK-1/-2) 小分子抑制剂。该公司已启动一项开放标签、多中心、Ib/IIa 期伞状主试验或 FIRELIGHT-1，以研究托沃拉非尼作为单一疗法或联合疗法，该试验由两项子研究组成。子研究 1 是针对 12 岁及以上患者进行托沃非尼单一疗法治疗的 IIa 期试验。
公司简介
公司代码DAWN
公司名称Day One Biopharmaceuticals Inc
上市日期May 27, 2021
CEODr. Jeremy Bender, Ph.D.
员工数量181
证券类型Ordinary Share
年结日May 27
公司地址2000 Sierra Point Parkway, Suite 501
城市BRISBANE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94005
电话16504840899
网址https://dayonebio.com/
公司代码DAWN
上市日期May 27, 2021
CEODr. Jeremy Bender, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.79M
+1.00%
Mr. Adam Dubow
Mr. Adam Dubow
General Counsel, Chief Compliance Officer and Secretary
General Counsel, Chief Compliance Officer and Secretary
59.22K
+14.58%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
40.48K
--
Ms. Lauren Merendino
Ms. Lauren Merendino
Chief Commercial Officer
Chief Commercial Officer
35.16K
+23.15%
Mr. Scott Garland
Mr. Scott Garland
Independent Director
Independent Director
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Natalie C. Holles
Ms. Natalie C. Holles
Independent Director
Independent Director
--
--
Dr. John A. Josey, Ph.D.
Dr. John A. Josey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles N. York, II
Mr. Charles N. York, II
Chief Financial Officer, Chief Operating Officer, Secretary
Chief Financial Officer, Chief Operating Officer, Secretary
--
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.79M
+1.00%
Mr. Adam Dubow
Mr. Adam Dubow
General Counsel, Chief Compliance Officer and Secretary
General Counsel, Chief Compliance Officer and Secretary
59.22K
+14.58%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
40.48K
--
Ms. Lauren Merendino
Ms. Lauren Merendino
Chief Commercial Officer
Chief Commercial Officer
35.16K
+23.15%
Mr. Scott Garland
Mr. Scott Garland
Independent Director
Independent Director
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
收入明细
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
暂无数据
地区USD
名称
营收
占比
United States
30.76M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Access Industries, Inc.
12.76%
Fidelity Management & Research Company LLC
11.23%
Atlas Venture
6.34%
The Vanguard Group, Inc.
5.85%
RA Capital Management, LP
5.68%
Other
58.15%
持股股东
持股股东
占比
Access Industries, Inc.
12.76%
Fidelity Management & Research Company LLC
11.23%
Atlas Venture
6.34%
The Vanguard Group, Inc.
5.85%
RA Capital Management, LP
5.68%
Other
58.15%
股东类型
持股股东
占比
Investment Advisor
30.95%
Investment Advisor/Hedge Fund
27.73%
Hedge Fund
19.66%
Corporation
12.76%
Venture Capital
12.02%
Individual Investor
4.32%
Research Firm
3.66%
Pension Fund
0.21%
Bank and Trust
0.18%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
384
113.17M
111.65%
-15.74M
2025Q1
400
113.26M
111.74%
-16.79M
2024Q4
385
112.87M
111.38%
-9.38M
2024Q3
370
111.03M
112.52%
+6.48M
2024Q2
350
93.62M
107.11%
-6.88M
2024Q1
332
91.68M
104.96%
-18.10M
2023Q4
322
94.91M
109.07%
-11.77M
2023Q3
305
94.81M
109.41%
-11.39M
2023Q2
294
96.37M
113.78%
+8.76M
2023Q1
256
77.45M
105.60%
-6.86M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Access Industries, Inc.
12.93M
12.76%
--
--
Aug 01, 2024
Fidelity Management & Research Company LLC
11.38M
11.23%
+670.68K
+6.26%
Mar 31, 2025
Atlas Venture
6.43M
6.34%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
5.93M
5.85%
+94.32K
+1.62%
Mar 31, 2025
RA Capital Management, LP
5.76M
5.68%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.18M
5.11%
+127.47K
+2.52%
Mar 31, 2025
Alyeska Investment Group, L.P.
4.06M
4.01%
+1.55M
+61.60%
Mar 31, 2025
Franklin Advisers, Inc.
3.98M
3.92%
+127.39K
+3.31%
Mar 31, 2025
Pictet Asset Management Ltd.
3.64M
3.59%
+145.52K
+4.17%
Mar 31, 2025
Braidwell LP
3.54M
3.49%
-1.34M
-27.43%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Products ETF
1.87%
Tema Oncology ETF
1.01%
Tema Neuroscience and Mental Health ETF
0.74%
ALPS Medical Breakthroughs ETF
0.45%
SPDR S&P Biotech ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.09%
WisdomTree US SmallCap Fund
0.09%
Invesco Nasdaq Biotechnology ETF
0.07%
Optimize Strategy Index ETF
0.07%
Fidelity Fundamental Small-Mid Cap ETF
0.07%
查看更多
Virtus LifeSci Biotech Products ETF
占比1.87%
Tema Oncology ETF
占比1.01%
Tema Neuroscience and Mental Health ETF
占比0.74%
ALPS Medical Breakthroughs ETF
占比0.45%
SPDR S&P Biotech ETF
占比0.16%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.09%
WisdomTree US SmallCap Fund
占比0.09%
Invesco Nasdaq Biotechnology ETF
占比0.07%
Optimize Strategy Index ETF
占比0.07%
Fidelity Fundamental Small-Mid Cap ETF
占比0.07%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
